CytoDyn appoints Robert E. Hoffman as new CEO, Jacob Lalezari shifts to research role
CytoDyn Inc. announced that Robert E. Hoffman will become chief executive officer on October 20, 2026, succeeding Dr. Jacob Lalezari. Lalezari, who has led the company since November 2023, will remain as Head of Research and Translational Sciences to advance leronlimab in solid‑tumor oncology. Hoffman, who joined CytoDyn as chief financial officer on May 15, 2025, will also continue as the principal accounting officer.
Why it matters
The company says the leadership change is intended to sharpen clinical execution and accelerate partnership opportunities for its oncology pipeline. Investors should watch for any impact on upcoming regulatory milestones and partnership discussions in 2027.
Key facts
- 1Robert E. Hoffman was appointed CEO, effective October 20, 2026. stocktitan.net
- 2Dr. Jacob Lalezari, CEO since November 2023, will become Head of Research and Translational Sciences. stocktitan.net
- 3Hoffman joined CytoDyn as CFO on May 15, 2025. stocktitan.net
- 4Hoffman will also retain his role as principal accounting officer. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.